Shone, GB
Charles Clifford Shone, Alderbury GB
Patent application number | Description | Published |
---|---|---|
20090274708 | Recombinant Toxin Fragments - Antigenic compositions are provided comprising a single chain polypeptide comprising first and second domains, wherein said first domain is a clostridial neurotoxin light chain or a fragment or a variant thereof and is capable of cleaving one or more vesicle or plasma membrane associated proteins essential to exocytosis; and said second domain is a clostridial neurotoxin heavy chain H | 11-05-2009 |
Clifford Shone, Wiltshire GB
Patent application number | Description | Published |
---|---|---|
20100291152 | CHEMICALLY MODIFIED PEPTIDES WITH IMPROVED IMMUNOGENICITY - The invention provides processes for improving the ability of a peptide to stimulate an immune response, comprising exposing the peptide to a chemical modifying agent. It further provides compositions comprising an antigenic peptide, wherein the peptide has been treated with a chemical modifying agent to improve its ability to stimulate an immune response. It also provides methods of stimulating an immune response in a mammal, comprising administering to the mammal an effective amount of a vaccine. | 11-18-2010 |
20100297180 | BOTULINUM NEUROTOXIN VACCINE - The invention provides compositions comprising an antigenic botulinum neurotoxin serotype E (BoNT/E) peptide, wherein the peptide has improved solubility and thus improved ability to stimulate an immune response against BoNT/E holotoxin. The composition may be used as part of a multivalent vaccine regimen via coordinated use with non-serotype E BoNT peptides, such as one or more BoNT/A and/or BoNT/B peptides. It further provides processes for manufacturing said BoNT/E peptide. It also provides methods of stimulating an immune response in a mammal, comprising administering to the mammal an effective amount of a BoNT/E and optionally one or more non-serotype E BoNT peptides such as one or more BoNT/A and/or BoNT/B peptides. | 11-25-2010 |
20120121607 | ANTIBODIES TO CLOSTRIDIUM DIFFICILE TOXINS - The present invention provides an antibody composition comprising ovine antibodies, for use in the prevention or treatment of | 05-17-2012 |
Clifford Shone, Salisbury GB
Patent application number | Description | Published |
---|---|---|
20130004561 | THERAPIES FOR PREVENTING OR SUPPRESSING CLOSTRIDIUM DIFFICILE INFECTION - The present invention provides an antibody composition comprising ovine antibodies, for use in the prevention or treatment of | 01-03-2013 |
20130266583 | CLOSTRIDIUM DIFFICILE ANTIGENS - The present invention relates to recombinant | 10-10-2013 |
Clifford C. Shone, Salisbury GB
Patent application number | Description | Published |
---|---|---|
20120034239 | PROTEINS WITH IMPROVED SOLUBILITY AND METHODS FOR PRODUCING AND USING SAME - A method is provided for improving the solubility of proteins, for example, bacterial toxins. In one embodiment, solubility is improved by introducing point mutations that replace cysteine residues capable of forming intermolecular disulfide bonds with other amino acid residues that do not form such bonds. By abrogating the ability of the cysteine residues to form inter-molecular disulfide bonds, aggregation of the protein is reduced, thereby improving the solubility of the protein. In another embodiment, solubility of the protein is improved by producing truncated forms of the protein that express the LHN domain and a fragment of the Hc domain. Proteins made according to the method of the invention are useful, for example, as immunodiagnostic agents and vaccine components. | 02-09-2012 |
Clifford C. Shone, Wiltshire GB
Patent application number | Description | Published |
---|---|---|
20090269358 | Proteins with Improved Solubility and Methods for Producing and Using Same - A method is provided for improving the solubility of proteins, for example, bacterial toxins. In one embodiment, solubility is improved by introducing point mutations that replace cysteine residues capable of forming intermolecular disulfide bonds with other amino acid residues that do not form such bonds. By abrogating the ability of the cysteine residues to form inter-molecular disulfide bonds, aggregation of the protein is reduced, thereby improving the solubility of the protein. In another embodiment, solubility of the protein is improved by producing truncated forms of the protein that express the LHN domain and a fragment of the Hc domain. Proteins made according to the method of the invention are useful, for example, as immunodiagnostic agents and vaccine components. | 10-29-2009 |
Clifford Charles Shone, Salisbury, Wiltshire GB
Patent application number | Description | Published |
---|---|---|
20090148888 | RECOMBINANT TOXIN FRAGMENTS - A single polypeptide is provided which comprises first and second domains. The first domain enables the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and the second domain enables the polypeptide to be translocated into a target cell or increases the solubility of the polypeptide, or both. The polypeptide thus combines useful properties of a clostridial toxin, such as a botulinum or tetanus toxin, without the toxicity associated with the natural molecule. The polypeptide can also contain a third domain that targets it to a specific cell, rendering the polypeptide useful in inhibition of exocytosis in target cells. Fusion proteins comprising the polypeptide, nucleic acids encoding the polypeptide and methods of making the polypeptide are also provided. Controlled activation of the polypeptide is possible and the polypeptide can be incorporated into vaccines and toxin assays. | 06-11-2009 |
Clifford Charles Shone, Salisbury GB
Patent application number | Description | Published |
---|---|---|
20090246827 | RECOMBINANT TOXIN FRAGMENTS - A single polypeptide is provided which comprises first and second domains. The first domain enables the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and the second domain enables the polypeptide to be translocated into a target cell or increases the solubility of the polypeptide, or both. The polypeptide thus combines useful properties of a clostridial toxin, such as a botulinum or tetanus toxin, without the toxicity associated with the natural molecule. The polypeptide can also contain a third domain that targets it to a specific cell, rendering the polypeptide useful in inhibition of exocytosis in target cells. Fusion proteins comprising the polypeptide, nucleic acids encoding the polypeptide and methods of making the polypeptide are also provided. Controlled activation of the polypeptide is possible and the polypeptide can be incorporated into vaccines and toxin assays. | 10-01-2009 |
20090269361 | Constructs for delivery of therapeutic agents to neuronal cells - A non-toxic polypeptide, for delivery of a therapeutic agent to a neuronal cell, comprises a binding domain that binds to the neuronal cell, and a translocation domain that translocates the therapeutic agent into the neuronal cell, wherein the translocation domain is not a H | 10-29-2009 |
20100022751 | RECOMBINANT TOXIN FRAGMENTS - A single polypeptide is provided which comprises first and second domains. The first domain enables the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and the second domain enables the polypeptide to be translocated into a target cell or increases the solubility of the polypeptide, or both. The polypeptide thus combines useful properties of a clostridial toxin, such as a botulinum or tetanus toxin, without the toxicity associated with the natural molecule. The polypeptide can also contain a third domain that targets it to a specific cell, rendering the polypeptide useful in inhibition of exocytosis in target cells. Fusion proteins comprising the polypeptide, nucleic acids encoding the polypeptide and methods of making the polypeptide are also provided. Controlled activation of the polypeptide is possible and the polypeptide can be incorporated into vaccines and toxin assays. | 01-28-2010 |
20150010580 | ANTIBODIES TO CLOSTRIDIUM DIFFICILE TOXINS - The present invention provides an antibody composition comprising ovine antibodies, for use in the prevention or treatment of | 01-08-2015 |
Clifford Charles Shone, Alderbury GB
Patent application number | Description | Published |
---|---|---|
20110028691 | RECOMBINANT TOXIN FRAGMENTS - A single polypeptide is provided which comprises first and second domains. The first domain enables the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and the second domain enables the polypeptide to be translocated into a target cell or increases the solubility of the polypeptide, or both. The polypeptide thus combines useful properties of a clostridial toxin, such as a botulinum or tetanus toxin, without the toxicity associated with the natural molecule. The polypeptide can also contain a third domain that targets it to a specific cell, rendering the polypeptide useful in inhibition of exocytosis in target cells. Fusion proteins comprising the polypeptide, nucleic acids encoding the polypeptide and methods of making the polypeptide are also provided. Controlled activation of the polypeptide, is possible and the polypeptide can be incorporated into vaccines and toxin assays. | 02-03-2011 |
Clifford Charles Shone, Wiltshire GB
Patent application number | Description | Published |
---|---|---|
20080319167 | Clostridial toxin derivatives able to modify peripheral sensory afferent functions - This invention describes a novel agent for the targeted control of a mammalian cell activity, in particular the agent is used to control the interaction of particular cell types with their external environment. The agent has applications as a pharmaceutical for the treatment of a variety of disorders. An agent according to the invention comprises three Domains B, T and E linked together in the following manner: Domain B-Domain T-Domain E where Domain B is the Binding Domain which binds the agent to a Binding Site on the cell which undergoes endocytosis to produce an endosome, Domain T is the Translocation Domain which translocates the agent (with or without the Binding Site) from within the endosome across the endosomal membrane into the cytosol of the cell, Domain E is the Effector Domain which inhibits the ability of the Recyclable Membrane Vesicles to transport the Integral Membrane Proteins to the surface of the cell. | 12-25-2008 |
20090131645 | Clostridial toxin derivatives able to modify peripheral sensory afferent functions - This invention describes a novel agent for the targeted control of a mammalian cell activity, in particular the agent is used to control the interaction of particular cell types with their external environment. The agent has applications as a pharmaceutical for the treatment of a variety of disorders. An agent according to the invention comprises three Domains B, T and E linked together in the following manner: Domain B-Domain T-Domain E where Domain B is the Binding Domain which binds the agent to a Binding Site on the cell which undergoes endocytosis to produce an endosome, Domain T is the Translocation Domain which translocates the agent (with or without the Binding Site) from within the endosome across the endosomal membrane into the cytosol of the cell, Domain E is the Effector Domain which inhibits the ability of the Recyclable Membrane Vesicles to transport the Integral Membrane Proteins to the surface of the cell. | 05-21-2009 |
20120141511 | CLOSTRIDIAL TOXIN DERIVATIVES ABLE TO MODIFY PERIPHERAL SENSORY AFFERENT FUNCTIONS - A novel agent for the targeted control of a mammalian cell activity can be used to control the interaction of particular cell types with their external environment. The agent has applications as a pharmaceutical for the treatment of a variety of disorders. An agent according to the invention comprises three Domains B, T and E, linked together in the following manner: Domain B-Domain T-Domain E where Domain B is the Binding Domain, which binds the agent to a Binding Site on the cell which undergoes endocytosis to produce an endosome; Domain T is the Translocation Domain, which translocates the agent from within the endosome across the endosomal membrane into the cytosol of the cell; and Domain E is the Effector Domain, which inhibits the ability of the Recyclable Membrane Vesicles to transport the Integral Membrane Proteins to the surface of the cell. | 06-07-2012 |
Clifford Charles Shone, Abingdon GB
Patent application number | Description | Published |
---|---|---|
20120128700 | CONSTRUCTS FOR DELIVERY OF THERAPEUTIC AGENTS TO NEURONAL CELLS - A non-toxic polypeptide, for delivery of a therapeutic agent to a neuronal cell, comprises a binding domain that binds to the neuronal cell, and a translocation domain that translocates the therapeutic agent into the neuronal cell, wherein the translocation domain is not a H | 05-24-2012 |
Peter A. Shone, Nottingham GB
Patent application number | Description | Published |
---|---|---|
20120150491 | MACHINE OPERATION MANAGEMENT - A method for managing machine operation comprising sensing a plurality of operational variables for a machine during use thereof so as to generate operational data for said variables. The operational data is processed so as to determine features within the operational data which are indicative of a divergence from a desired operational state of the machine. Confidence values associated with said features are determined and used to assess whether the plurality of features and associated confidence values are indicative of a predetermined diagnosis for said machine. A confidence value for said diagnosis is determined based upon the associated feature confidence values and used to generate a signal indicative of an operational state of the machine. The invention may be used for engine health monitoring applications and may be used for determining necessary servicing or repair work for the engine. | 06-14-2012 |